Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134720 | 0.89 | DDB1 (0.44) | DDB1CRBNALDH1A1TSHRPARP1 | |
| SCHEMBL25935493 | 0.87 | DDB1 (0.46) | DDB1CRBNALDH1A1TSHRPARP1 | |
| SCHEMBL25935495 | 0.86 | DDB1 (0.56) | DDB1CRBNALDH1A1TSHRPARP1 | |
| SCHEMBL30501247 | 0.84 | DDB1 (0.41) | DDB1CRBNALDH1A1TSHRPARP1 | |
| SCHEMBL31447691 | 0.83 | DDB1 (0.53) | DDB1CRBNSIGMAR1DRD2 | |
| SCHEMBL29013153 | 0.83 | DDB1 (0.43) | DDB1CRBNALDH1A1TSHRPARP1 | |
| SCHEMBL24671840 | 0.83 | HSD11B1 (0.39) | PARP1SIGMAR1DRD2 | |
| SCHEMBL23121762 | 0.83 | MGLL (0.38) | TSHR | |
| SCHEMBL30066376 | 0.83 | HSD11B1 (0.39) | PARP1SIGMAR1DRD2 | |
| SCHEMBL30009715 | 0.83 | MGLL (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | DDB1 1245/4885CRBN 324/4885ALDH1A1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.